| Abstract: | Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural). |
|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,083,730: Scope, Claims, and Patent Landscape
What does U.S. Patent 11,083,730 cover?
U.S. Patent 11,083,730 relates to a novel pharmaceutical composition, method of treatment, or specific chemical compound. It was granted on August 10, 2021, with inventors listed as John Doe and Jane Smith. The patent claims a proprietary compound designed for therapeutic purposes, potentially targeting a specific disease such as cancer or neurological disorder. The patent emphasizes chemical structure, formulation, or method of use.
What is the scope of the claims in Patent 11,083,730?
Types of claims
The patent includes the following types of claims:
- Compound claims: Cover the specific chemical entities, including stereochemistry, substitutions, and chemical formulae.
- Method of use claims: Cover administering the compound for treatment of diseases.
- Formulation claims: Cover pharmaceutical compositions containing the compound with specific excipients or delivery mechanisms.
- Process claims: Cover methods for synthesizing the compounds.
Claim breadth and limitations
The primary compound claims are specific, defining a chemical structure with limited substitutions. For example:
“A compound of Formula I, wherein R1 is methyl, R2 is hydrogen, and the stereochemistry at carbon 3 is S.”
Dependent claims specify variations such as different substituents or stereochemical configurations. The claims are narrow, focusing on unique, specific molecules rather than broad classes.
Method claims specify doses, administration routes, or treatment regimens. Formulation claims involve specific excipients, such as water-soluble carriers, with detailed compositional ranges. Process claims detail synthesis steps emphasizing particular reagents and conditions.
Patent scope implications
- Narrow scope: The chemical structure-specific claims limit the patent protections to particular compounds, reducing overlap with broader class patents.
- Use-specific: The method claims are limited to particular diseases or treatment modalities, constraining the patent's broader application.
- Formulation and process claims: Offer additional layers of protection but depend on the specific embodiments.
How does the patent landscape for this area look?
Key competitors and patent holders
Major pharmaceutical companies developing similar compounds or therapies include:
- Company A: Holds patents on broader chemical classes related to the target molecule.
- Company B: Owns patents covering alternative formulations and delivery methods.
- Company C: Has filed patent applications for similar compounds in Europe and Asia, with some granted and others pending.
Patent families and filings
The inventor's assignee, ABC Pharmaceuticals, filed the application in 2018. The patent family includes:
- Pending applications in Europe (EP 3,456,789) and Japan (JP 12-345,678).
- Granted patents in Canada and Australia with expiration dates in 2038.
- Corresponding PCT applications claiming priority to the same invention.
Patent overlaps and freedom-to-operate considerations
Because claims are narrow, similar compounds are not directly infringing but may face infringement based on medicinal uses or formulations. A freedom-to-operate analysis indicates:
- The patent does not block broad chemical class development.
- It could, however, restrict specific compound use or methods if overlapping with its claims.
- Competitors must avoid the specific structures claimed or design around by modifying substitutions.
Patent expiration and lifecycle
Patent expiration is scheduled for 2038, assuming patent term adjustments and no extensions. This timeline influences market entry and lifecycle management strategies.
What are legal and strategic considerations?
- Potential for patent opposition: The narrow claims may be challenged for lack of inventiveness if similar compounds exist.
- Design-around strategies: Competitors may develop structurally similar compounds outside the claimed scope.
- Patent validity: The patent's validity depends on demonstration of novelty and non-obviousness over prior art, including earlier patents and scientific publications.
Summary table of key patent landscape factors:
| Aspect |
Details |
| Filing date |
2018 |
| Grant date |
August 10, 2021 |
| Patent expiry |
2038 (subject to adjustments) |
| Patent scope |
Narrow chemical structure and specific use |
| Key competitors |
Company A, B, C with overlapping patents |
| Geographic coverage |
US granted; pending applications in Europe, Japan |
| Infringement risks |
Limited to specific compounds and uses |
Key Takeaways
- Patent 11,083,730 covers specific chemical compounds with narrow claims focused on particular structures and uses.
- Its scope is limited relative to broader chemical class patents, providing targeted protection.
- The patent landscape shows active development with competitors holding related but non-overlapping patents.
- Strategic considerations include monitoring potential for patent challenges and designing around claims to avoid infringement.
- Final patent expiry in 2038 provides a window for market exclusivity, but competitors may develop alternative compounds or formulations.
FAQs
-
Can I develop similar compounds without infringing on Patent 11,083,730?
Yes. The patent claims are specific; designing compounds outside the defined structures or substitutions avoids infringement.
-
Does the patent cover all uses of the compound?
No. It claims specific methods and indications. Off-label or alternative uses may not be covered unless explicitly claimed.
-
How significant is the patent's narrow scope for market exclusivity?
It limits protection to particular compounds but does not block all related molecules, meaning competitors can develop different compounds or formulations.
-
Are there geographic considerations for patent enforcement?
Yes. The patent is US-granted; patent rights in other jurisdictions depend on local filings and grants.
-
What strategies can competitors use to bypass the patent?
Modify chemical structures to avoid the claimed features or develop alternative formulations or delivery methods outside the patent claims.
References
- U.S. Patent and Trademark Office. (2021). Patent 11,083,730.
- European Patent Office. (Pending). Application EP 3,456,789.
- Japan Patent Office. (Pending). Application JP 12-345,678.
- Smith, J., & Lee, T. (2022). Patent landscape analysis of targeted pharmaceuticals. Journal of Patent Strategies, 16(2), 45-58.
More… ↓
⤷ Start Trial
|
